---
figid: PMC4150259__bjc2014215f1
figlink: /pmc/articles/PMC4150259/figure/fig1/
number: F1
caption: An overview of oncogenic KRAS-driven RAF/MEK/ERK and PI3K/PDK1/AKT signalling
  networks in pancreatic cancer. Mutationally activated oncogenic KRAS engages the
  PI3K-PDK1-AKT pathway to drive cancer initiation, progression and maintenance. Additionally,
  activated KRAS signals through the canonical mitogen-activated protein kinase pathway
  via RAF-MEK1/2-ERK1/2. KRAS activity is enhanced by positive feedback activation
  of the epidermal growth factor receptor (EGFR) and possibly by other receptor tyrosine
  kinases (RTKs) that are engaged by autocrine and paracrine stimuli. Negative feedback
  loops and inhibitory as well as activating cross-signalling exist at various levels.
  Activating pro-tumourigenic signalling connections are depicted as arrows in green;
  inhibitory anti-tumourigenic pathways are shown as solid lines headed by a vertical
  line in red. Arrows in red depict activating anti-tumourigenic feedback loops. The
  asterisk (KRAS*) represents the mutational activation of KRAS.
pmcid: PMC4150259
papertitle: Oncogenic KRAS signalling in pancreatic cancer.
reftext: S Eser, et al. Br J Cancer. 2014 Aug 26;111(5):817-822.
pmc_ranked_result_index: '10284'
pathway_score: 0.9581672
filename: bjc2014215f1.jpg
figtitle: An overview of oncogenic KRAS-driven RAF/MEK/ERK and PI3K/PDK1/AKT signalling
  networks in pancreatic cancer
year: '2014'
organisms:
- Homo sapiens
ndex: ca65c242-ded8-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4150259__bjc2014215f1.html
  '@type': Dataset
  description: An overview of oncogenic KRAS-driven RAF/MEK/ERK and PI3K/PDK1/AKT
    signalling networks in pancreatic cancer. Mutationally activated oncogenic KRAS
    engages the PI3K-PDK1-AKT pathway to drive cancer initiation, progression and
    maintenance. Additionally, activated KRAS signals through the canonical mitogen-activated
    protein kinase pathway via RAF-MEK1/2-ERK1/2. KRAS activity is enhanced by positive
    feedback activation of the epidermal growth factor receptor (EGFR) and possibly
    by other receptor tyrosine kinases (RTKs) that are engaged by autocrine and paracrine
    stimuli. Negative feedback loops and inhibitory as well as activating cross-signalling
    exist at various levels. Activating pro-tumourigenic signalling connections are
    depicted as arrows in green; inhibitory anti-tumourigenic pathways are shown as
    solid lines headed by a vertical line in red. Arrows in red depict activating
    anti-tumourigenic feedback loops. The asterisk (KRAS*) represents the mutational
    activation of KRAS.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT3
  - MAPK3
  - MTOR
  - EGF
  - EGFR
  - PIK3R6
  - PIK3R5
  - AKT1
  - RAF1
  - PIK3CD
  - KRAS
  - BRAF
  - MAPK1
  - AKT2
  - PIK3CG
  - PIK3R3
  - PDK1
  - PIK3CB
  - ARAF
  - MAP2K1
  - PIK3R4
  - PTEN
  - MAP2K2
  - PIK3CA
  - Cancer
  - Cardiomyopathy
  - Lung cancer
genes:
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: EGF,
  symbol: EGF
  source: hgnc_symbol
  hgnc_symbol: EGF
  entrez: '1950'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: CRAF
  symbol: c-Raf
  source: hgnc_alias_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: KRAS
  symbol: KRAS
  source: hgnc_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: ERK1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PDK1
  symbol: PDK1
  source: hgnc_symbol
  hgnc_symbol: PDK1
  entrez: '5163'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: MEK1/2
  symbol: MEK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: MEK1/2
  symbol: MEK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
figid_alias: PMC4150259__F1
redirect_from: /figures/PMC4150259__F1
figtype: Figure
---
